Hey everyone! I'm back to give a quick update on $APRE since it's been awhile. It hasn't been on the run much today, but we've seen some nice moves to the upside these last few days!

If you don't know, Aprea Therapeutics is a clinical-stage biopharmaceutical company specializing in precision oncology through synthetic lethality. Their pipeline includes two key candidates:

• APR-1051: An oral WEE1 inhibitor currently in Phase 1 trials for advanced solid tumors. Preliminary data indicate that APR-1051 is well-tolerated with no unexpected toxicities.
• ATRN-119: A macrocyclic ATR inhibitor undergoing Phase 1/2a studies, with initial efficacy data anticipated in the second half of 2025.

Key Considerations:

• Pipeline Progress: Ongoing clinical trials for APR-1051 and ATRN-119 are crucial for Aprea's growth.
• Financial Position: The company's cash reserves are expected to support operations into late 2025.
• Market Dynamics: Advancements in synthetic lethality could position Aprea favorably within the oncology sector.

Aprea Therapeutics is advancing its oncology pipeline with promising candidates. Investors should monitor clinical trial outcomes and financial updates to assess potential growth.

Communicated Disclaimer: NFA, please do your own research!

Sources 1 2 3